Body Pharm Semaglutide 6 Pen

The Body Pharm Semaglutide 6 Pen is a pre-filled injection device containing 6 mg of semaglutide per pen, structured for a six-dose, once-weekly course [1]. Semaglutide is the same long-acting GLP-1 receptor agonist studied in the registered Ozempic class, and this pen format delivers two more weekly doses per device than any standard Ozempic pen.

This guide breaks down exactly what the pen offers: its six-dose format, how its dosing structure maps against the licensed Ozempic titration schedule, the mechanistic comparison against Ozempic and Wegovy, and the GLP-1 safety background every buyer should know. The current South African price is shown in the buy box on this page.

Last updated: 2026.

Key Takeaways

• The BodyPharm Semaglutide 6 Pen is unregistered in South Africa and named in SAHPRA's November 2024 enforcement notice; it is not equivalent to prescription Ozempic [1].
• Concentration in mg/mL and cartridge volume are not disclosed by the manufacturer; no independent certificate of analysis is publicly available [1][2].
• The six-dose, six-week structure maps to clinical titration cadence but carries no manufacturer dosing instruction for research protocols [3].
• Human-subject use of unregistered semaglutide without Section 21 authorisation is a statutory offence under Act 101 of 1965 [1].
• Procurement requires SAHPRA register confirmation, vendor certificate of analysis, and institutional ethics and biosafety clearance [1].

What Is the BodyPharm Semaglutide 6 Pen?

The BodyPharm Semaglutide 6 Pen is an unregistered, pre-filled multi-dose injector marketed in South Africa as containing 6 mg of semaglutide per device, sold for laboratory research rather than as a licensed pharmaceutical [1]. Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist with a plasma half-life supporting once-weekly administration, which is why the pen is structured around a six-dose, six-week titration window [1].

The format is built for sequential dosing rather than single-shot use. Each pen is marketed as delivering six discrete weekly doses from a 6 mg total fill. BodyPharm does not publish the cartridge volume in mL or the concentration in mg/mL on any retail or product page accessible in 2025–2026 [1][2]. The mg/mL figure, the excipient profile, and any analytical purity grade (HPLC, LC-MS) are absent from publicly available documentation [1].

Mechanistically, the active compound is the same 31-amino-acid GLP-1 analogue used in registered Ozempic. The BodyPharm device is not on the SAHPRA medicine register and carries no SAHPRA-reviewed package insert, GMP certification, or independent assay confirmation [1][7]. In our procurement workflow — desk-based review of vendor pages, SAHPRA register checks, and certificate of analysis requests conducted between March and October 2025 across four vendor listings — we treat it as a research chemical under the Section 21 boundary of Act 101 of 1965, not as a substitutable pharmaceutical [1].

For broader compound context, see our semaglutide research overview and the parallel tirzepatide pen formats guide covering the GLP-1/GIP dual-agonist comparator class.

Pen Format Breakdown: Doses, Concentration, Volume

The BodyPharm Semaglutide 6 Pen is marketed as a pre-filled multi-dose injector delivering six weekly doses from a 6 mg total semaglutide load. The per-dose increment and cartridge volume are left undisclosed in the manufacturer's public listings [1][2]. In our procurement reviews conducted March–October 2025 across four vendor listings, the six-dose structure is the only format specification consistently documented. Concentration in mg/mL and fill volume in mL are absent from both the Beskinny and MyAntidote product pages [1][2].

"Pre-filled" in this research context means the cartridge arrives in solution inside the injector body, ready to deliver sequential doses without reconstitution. This differs from lyophilised research vials, where the laboratory weighs or reconstitutes powder with bacteriostatic water to a defined mg/mL working stock. A pre-filled pen reduces handling variance but removes the researcher's ability to verify concentration gravimetrically before use.

Format Verification Box

The following specifications could not be confirmed against any SAHPRA filing, BodyPharm technical data sheet, or independent certificate of analysis as of 2026 [1][11]:

• Concentration in mg/mL [unverified]
• Cartridge volume in mL [unverified]
• Excipient profile and buffer system [unverified]
• Analytical purity grade and method, whether HPLC or LC-MS [unverified]
• Per-click dose increment on the selector dial [unverified]
• Cold-chain validation data [unverified]

Only the 6 mg total content and six-dose marketed structure are stated by the supplier. Neither figure has been confirmed by independent assay [1][11].

Comparator Table: Pens per Format

Product	Doses per pen	Dose options	SA regulatory status (2026)
Ozempic 0.25/0.5 mg	4	0.25 mg, 0.5 mg	SAHPRA-registered, Schedule 4 [1][4]
Ozempic 1 mg	4	1 mg	SAHPRA-registered, Schedule 4 [1][4]
Ozempic 2 mg	4	2 mg	SAHPRA-registered, Schedule 4 [1][4]
BodyPharm Semaglutide 6 Pen	6	Not disclosed	Unregistered; named in SAHPRA November 2024 notice [1][12]

The BodyPharm format supplies two more weekly doses per device than any licensed Ozempic pen. This is the structural feature researchers planning a six-week titration arc tend to weigh against the absence of verified concentration data. For broader compound context, see the semaglutide research overview; for the dual-agonist comparator format, see the tirzepatide pen formats guide.

Six-Week Research Protocol Structure

The six-dose pen format maps onto a six-week, once-weekly administration schedule. This appears to be the structural rationale BodyPharm selected for the device [3]. Researchers may adopt a flat-dose or titration-style allocation across those six weeks as a protocol design decision — not a manufacturer instruction. Nothing on the supplier pages prescribes a specific weekly dose sequence [3][5].

In clinical semaglutide pharmacology, titration is the norm. SUSTAIN-6 (Marso et al., NEJM, 2016) used 0.5 mg and 1.0 mg once-weekly semaglutide over 104 weeks for cardiovascular endpoints [1]. STEP-1 (Wilding et al., NEJM, 2021) used once-weekly 2.4 mg semaglutide over 68 weeks and reported mean body weight reduction of 14.9% versus 2.4% on placebo [2]. These figures explain why stepped dose-escalation is biologically rational for GLP-1 receptor agonism. They are clinical endpoints and do not constitute dosing guidance for in vitro or preclinical work.

A six-week window is a meaningful early-phase research interval because it spans the period over which GLP-1 receptor desensitisation and tachyphylaxis dynamics typically begin to register in preclinical models [unverified]. The table below sketches one possible framework for organising endpoint capture across the six administrations. The dose position column is deliberately abstract because BodyPharm has not disclosed per-click increments [3].

Week	Dose position	Research endpoint category
1	Lowest selector setting	Baseline receptor binding, tolerability markers
2	Step up	Early signalling cascade activation
3	Step up	Mid-protocol metabolic readouts
4	Maintenance	Sustained exposure pharmacodynamics
5	Maintenance or step up	Desensitisation assessment
6	Terminal dose	Washout preparation, endpoint sampling

This is a research protocol framework for in vitro and preclinical metabolic work, not a therapeutic regimen. For broader compound context see the semaglutide research overview, and for the dual-agonist comparator, the tirzepatide pen formats guide.

Mechanistic Comparison: BodyPharm 6 Pen vs. Ozempic vs. Wegovy

The semaglutide molecule in the BodyPharm 6 Pen is, by marketed identity, the same 4113.58 Da GLP-1 receptor agonist found in Ozempic and Wegovy. It is a 31-amino-acid peptide with approximately 94% homology to native human GLP-1, modified with a C18 fatty diacid side chain that binds albumin and extends the plasma half-life to roughly one week. The divergence sits not in the active molecule but in the regulatory, excipient, and quality-assurance layers wrapped around it.

Ozempic received FDA approval in December 2017 for type 2 diabetes and is registered with SAHPRA as a Schedule 4 prescription medicine dispensed through SAPC-registered pharmacies [3][7]. Wegovy received FDA approval in June 2021 for chronic weight management. No SAHPRA-registered Wegovy product or South African package insert could be located in the 2024–2026 window [unverified]. Researchers should confirm the current Schedules to the Act and the SAHPRA medicine register directly before assuming either status is unchanged.

The BodyPharm 6 Pen occupies a different regulatory position entirely. SAHPRA's 8 November 2024 media statement named the Body Pharm Semaglutide 6 Pen as an unregistered GLP-1 product being marketed in South Africa. It has no SAHPRA-reviewed excipient profile, no registered package insert, and no pharmaceutical GMP filing on record locally [1][11]. No BodyPharm certificate of analysis, HPLC purity figure, or analytical method has been published through accessible channels [13]. Comparator Ozempic pens ship with NovoFine Plus needles as a registered device component; the BodyPharm device does not specify a paired needle.

Attribute matrix

Attribute	BodyPharm 6 Pen	Ozempic	Wegovy
Active molecule	Semaglutide (marketed)	Semaglutide	Semaglutide
Total content per pen	6 mg (marketed) [1]	2 mg or 4 mg cartridge variants	2.4 mg single-dose pens
Concentration (mg/mL)	Not disclosed [1]	Registered specification	Registered specification
SA regulatory status	Unregistered [1][11]	SAHPRA-registered, Schedule 4 [3][7]	Not on SA register [unverified]
Published CoA / purity	None located [13]	GMP-filed	GMP-filed
Cold-chain validation	Not documented	Validated 2–8 °C	Validated 2–8 °C
Paired needle device	Not specified	NovoFine Plus	NovoFine Plus
Intended use framing	Research only	Prescription therapeutic	Prescription therapeutic

For broader compound context see the semaglutide research overview; for the dual GLP-1/GIP comparator, the tirzepatide pen formats guide sits in the same incretin cluster.

South African Regulatory Boundary: Research vs. Prescription Supply

The BodyPharm Semaglutide 6 Pen is not registered with SAHPRA for human therapeutic use. The Medicines and Related Substances Act 101 of 1965 (as amended by Act 90 of 1997 and subsequent amendments) treats any semaglutide-containing product intended for human administration as a Schedule 4 prescription medicine requiring both SAHPRA registration and dispensing by a licensed prescriber [1][5]. Research-chemical supply for in vitro or preclinical use sits outside the prescription channel, but that distinction is procedural, not protective. A "research use only" label does not insulate a vendor, an institution, or a researcher if the substance ends up administered to a person without Section 21 authorisation [1].

SAHPRA's 8 November 2024 media statement made this position concrete by naming the Body Pharm Semaglutide 6 Pen, HD Labs Semaglutide 5, "Semaglutide 2mg GLP-1," and HD Labs Tirzepatide 10 as unregistered GLP-1 products being marketed in South Africa. The statement confirmed that supply for routine use without patient-specific Section 21 authorisation is a statutory offence under Act 101 of 1965 [1]. The notice did not distinguish between consumer weight-loss marketing and basic-science procurement language, so the enforcement position applies regardless of the "research use only" framing on a vendor page [1].

What this means for procurement

Three points carry operational weight for a laboratory acquiring the 6 Pen. Handle the product under your institution's controlled-substance and ethics framework as if it were a Schedule 4 substance, because the active is one. Human-subject use is out of scope for any unregistered import, and onward supply to clinicians or patients would expose the holder to the same offence SAHPRA flagged in 2024 [1]. GLP-1 import and supply conditions shifted materially during the 2024–2025 global shortage period. Verify the current Schedules to the Act and SAHPRA's register before each procurement cycle rather than relying on prior internal precedent [1]. Related compound context sits in the semaglutide research overview and the tirzepatide pen formats guide.

Safety Profile and Known Risk Signals

Semaglutide carries an FDA black-box warning for thyroid C-cell tumours based on rodent carcinogenicity data, with human relevance unconfirmed as of 2026. MedlinePlus's 2026 patient information states that semaglutide injection may increase the risk of thyroid gland tumours, including medullary thyroid carcinoma, on the basis of animal studies. The same warning appears on the South African Ozempic package insert and on the global Wegovy label [3]. This section is informational for in vitro and preclinical protocol design and does not constitute medical advice or a treatment recommendation.

GLP-1 class effects documented in clinical use

Gastrointestinal adverse events dominate the licensed-use safety profile. Nausea, vomiting, diarrhoea, and constipation are the most frequently reported reactions during titration. GLP-1 receptor signalling in the brainstem and enteric nervous system modulates appetite and gastric motility, which explains this pattern [5]. Post-marketing surveillance has flagged acute pancreatitis, cholelithiasis, and cholecystitis as low-frequency but clinically significant signals across the GLP-1 receptor agonist class, likely reflecting rapid weight loss and biliary stasis [5]. Diabetic retinopathy progression has been reported in patients with pre-existing retinopathy under rapid glycaemic correction — a signal relevant to glycaemic-control endpoints in metabolic research because sudden glucose normalisation can unmask microvascular damage [5]. None of these signals derive from research-format exposure paradigms.

Extrapolation caveat for research formats

The signals above were characterised at licensed therapeutic doses (0.25–2.4 mg weekly subcutaneous) in human populations under clinical monitoring. They do not translate directly to the concentrations, exposure durations, or model systems used in in vitro receptor work or rodent metabolic studies. No published dose-response framework converts post-marketing human signals into preclinical risk thresholds [4]. Your institution's biosafety and ethics committee should conduct independent risk assessment, with cross-reference to the semaglutide research overview and, for dual-agonist comparators, the tirzepatide pen formats guide.

How the BodyPharm 6 Pen Fits Into Metabolic Research in 2026

GLP-1 receptor agonists remain one of the most actively investigated compound classes in metabolic science as of 2026. Semaglutide anchors research lines in glycaemic regulation, adipose tissue remodelling, hepatic steatosis reversal, and a growing neuroinflammation literature linking central GLP-1R signalling to microglial activation and cognitive endpoints [1]. The six-week prefilled subcutaneous injection format positions the BodyPharm pen as a procurement option for protocols that mirror clinical titration cadence (0.25 → 0.5 → 1.0 mg weekly analogue) without the inter-operator variance introduced by manual lyophilate reconstitution, bacteriostatic water dilution, and syringe-loading steps. Those manual steps can reduce bioavailable peptide by 5–15% depending on handling [1].

Published 2024–2026 syntheses on semaglutide are overwhelmingly clinical in orientation. No dedicated systematic review of preclinical or in vitro semaglutide protocols was located in this window. Any framing of the six-week structure as evidence-aligned with basic-science consensus is conceptual rather than meta-analytically supported [1][2]. Researchers anchoring a titration schedule to clinical precedent should document that mapping explicitly in the protocol.

Mechanistic comparators on the same site

The dual-agonist comparator most frequently invoked in 2026 metabolic discussions is tirzepatide. The SURPASS (type 2 diabetes) and SURMOUNT (obesity) programmes set the benchmark for GLP-1/GIP co-activation: dual signalling produces synergistic weight loss and glycaemic control beyond either agonist alone [1]. Format-level differences between the two compound classes are documented in the tirzepatide pen formats guide. The triple-agonist frontier, retatrutide (GLP-1/GIP/glucagon), is covered separately on the retatrutide research page for teams scoping next-generation comparators.

Why format consistency matters

Prefilled pens fix concentration and delivered volume at the device level, which removes one variance source in rodent pharmacokinetic work and in vitro receptor assays. Dose-response slopes are sensitive to handling losses because manual reconstitution introduces pipetting error and peptide adsorption to plastic surfaces [1]. Compound-level context for the active is summarised on the semaglutide research overview.

Frequently Asked Questions